Noile-Immune Biotech Inc 4893
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- JPY 161.00
- Day Range
- JPY 168.00–211.00
- 52-Week Range
- JPY 150.00–775.00
- Bid/Ask
- JPY 170.00 / JPY 174.00
- Market Cap
- JPY 7.49 Bil
- Volume/Avg
- 12.2 Mil / 654,728
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 22.64
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Noile-Immune Biotech Inc is engaged in the development of novel cancer immunotherapy including CAR-T cell therapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 33
- Website
- https://www.noile-immune.com
Comparables
Valuation
|
Metric
|
4893
|
4563
|
4978
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.32 | 0.37 | 1.49 |
Price/Sales | 22.64 | 60.63 | 4.57 |
Price/Cash Flow | — | — | — |
Price/Earnings
4893
4563
4978
Financial Strength
|
Metric
|
4893
|
4563
|
4978
|
|---|---|---|---|
Quick Ratio | 65.18 | 1.68 | 11.63 |
Current Ratio | 66.28 | 2.38 | 12.43 |
Interest Coverage | — | — | — |
Quick Ratio
4893
4563
4978
Profitability
|
Metric
|
4893
|
4563
|
4978
|
|---|---|---|---|
Return on Assets (Normalized) | −19.85% | −16.00% | −0.30% |
Return on Equity (Normalized) | −20.61% | −19.90% | −0.32% |
Return on Invested Capital (Normalized) | −20.61% | −19.26% | −0.82% |
Return on Assets
4893
4563
4978
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mmmvlkcx | Tqypv | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xqfmqmmzg | Tgmktd | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wglctgts | Pxxkfq | $97.8 Bil | |
MRNA
| Moderna Inc | Qsdgcdjq | Byz | $41.3 Bil | |
ARGX
| argenx SE ADR | Zfvqvzdx | Tbbw | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Zbfqqjp | Ftgq | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qqnbmph | Kmphcd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dnnddsw | Jlmndw | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dhpfrhwr | Clchlzp | $12.5 Bil | |
INCY
| Incyte Corp | Hlkhwchq | Pztsfw | $11.6 Bil |